MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents
暂无分享,去创建一个
S. Nordeen | E. Howe | D. Cochrane | N. Spoelstra | J. Richer | Dawn R. Cochrane | Nicole S. Spoelstra | Erin N. Howe | Steven K. Nordeen | Jennifer K. Richer
[1] S. Horwitz,et al. Wild-type class I β-tubulin sensitizes Taxol-resistant breast adenocarcinoma cells harboring a β-tubulin mutation , 2007 .
[2] G. Berx,et al. DeltaEF1 is a transcriptional repressor of E-cadherin and regulates epithelial plasticity in breast cancer cells , 2005, Oncogene.
[3] D. Peeper,et al. Critical role for TrkB kinase function in anoikis suppression, tumorigenesis, and metastasis. , 2007, Cancer research.
[4] G. Goodall,et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1 , 2008, Nature Cell Biology.
[5] Ie-Ming Shih,et al. Pathogenesis of Ovarian Cancer: Lessons From Morphology and Molecular Biology and Their Clinical Implications , 2008, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.
[6] P. Chapdelaine,et al. Decidualization and maintenance of a functional prostaglandin system in human endometrial cell lines following transformation with SV40 large T antigen. , 2006, Molecular human reproduction.
[7] Sun-Mi Park,et al. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. , 2008, Genes & development.
[8] C. Dumontet,et al. Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents? , 2008, The Lancet. Oncology.
[9] L. Vahdat. Clinical studies with epothilones for the treatment of metastatic breast cancer. , 2008, Seminars in oncology.
[10] R. Place,et al. MicroRNA-373 induces expression of genes with complementary promoter sequences , 2008, Proceedings of the National Academy of Sciences.
[11] S. Spivack,et al. Overexpression of the microRNA hsa-miR-200c leads to reduced expression of transcription factor 8 and increased expression of E-cadherin. , 2007, Cancer research.
[12] S. Kyo,et al. Successful immortalization of endometrial glandular cells with normal structural and functional characteristics. , 2003, The American journal of pathology.
[13] E. Martinelli,et al. Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.
[14] A. Russo,et al. Increased Expression of Leptin and the Leptin Receptor as a Marker of Breast Cancer Progression: Possible Role of Obesity-Related Stimuli , 2006, Clinical Cancer Research.
[15] K. Leslie,et al. Models representing type I and type II human endometrial cancers: Ishikawa H and Hec50co cells. , 2007, Gynecologic oncology.
[16] W. Filipowicz,et al. Inhibition of Translational Initiation by Let-7 MicroRNA in Human Cells , 2005, Science.
[17] M. Kavallaris,et al. Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. , 1997, The Journal of clinical investigation.
[18] S. Richard,et al. Target RNA motif and target mRNAs of the Quaking STAR protein , 2005, Nature Structural &Molecular Biology.
[19] J. García-Verdugo,et al. Disruption of Eph/ephrin signaling affects migration and proliferation in the adult subventricular zone , 2000, Nature Neuroscience.
[20] Robert M. Gemmill,et al. WNT7a induces E-cadherin in lung cancer cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[21] K. Horwitz,et al. The transcription factor ZEB1 is aberrantly expressed in aggressive uterine cancers. , 2006, Cancer research.
[22] O. Kent,et al. A small piece in the cancer puzzle: microRNAs as tumor suppressors and oncogenes , 2006, Oncogene.
[23] C. Croce,et al. MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[24] W. McCluggage,et al. My approach to and thoughts on the typing of ovarian carcinomas , 2007, Journal of Clinical Pathology.
[25] R. Foisner,et al. The transcription factor ZEB1 (deltaEF1) represses Plakophilin 3 during human cancer progression. , 2007, FEBS letters.
[26] L. Pusztai,et al. Markers predicting clinical benefit in breast cancer from microtubule-targeting agents. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.
[27] Jens Einenkel,et al. Histopathology of endometrial hyperplasia and endometrial carcinoma: an update. , 2007, Annals of diagnostic pathology.
[28] R. Kaplan,et al. Priming the 'soil' for breast cancer metastasis: the pre-metastatic niche. , 2006, Breast disease.
[29] Patrick Neven,et al. Endometrial cancer. , 2005, Lancet.
[30] Wayne Tam,et al. MicroRNAs in tumorigenesis: a primer. , 2007, The American journal of pathology.
[31] J. Grande,et al. Leptin Receptor-Deficient MMTV-TGF-α/Leprdb Leprdb Female Mice Do Not Develop Oncogene-Induced Mammary Tumors , 2004 .
[32] Quynh-Thu Le,et al. Lysyl oxidase is essential for hypoxia-induced metastasis , 2006, Nature.
[33] A. Paradiso,et al. Biomarkers predictive for clinical efficacy of taxol-based chemotherapy in advanced breast cancer. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[34] S. Richard,et al. New implications for the QUAKING RNA binding protein in human disease , 2008, Journal of neuroscience research.
[35] Eduard Batlle,et al. Snail Induction of Epithelial to Mesenchymal Transition in Tumor Cells Is Accompanied by MUC1 Repression andZEB1 Expression* , 2002, The Journal of Biological Chemistry.
[36] D. Theodorescu,et al. RhoGDI2: a new metastasis suppressor gene: discovery and clinical translation. , 2007, Urologic oncology.
[37] Meenakshi Singh,et al. ZEB1 expression in type I vs type II endometrial cancers: a marker of aggressive disease , 2008, Modern Pathology.
[38] R. Foisner,et al. The transcription factor ZEB1 (δEF1) promotes tumour cell dedifferentiation by repressing master regulators of epithelial polarity , 2007, Oncogene.
[39] V. Fedele,et al. Cytoskeleton and paclitaxel sensitivity in breast cancer: The role of β‐tubulins , 2007 .
[40] M. Henkemeyer,et al. EphB Receptors Regulate Stem/Progenitor Cell Proliferation, Migration, and Polarity during Hippocampal Neurogenesis , 2007, The Journal of Neuroscience.
[41] J. Annereau,et al. Potential mechanisms of resistance to microtubule inhibitors. , 2008, Seminars in oncology.
[42] J. Erler,et al. Lysyl oxidase mediates hypoxic control of metastasis. , 2006, Cancer research.
[43] T. Funahashi,et al. High expression of leptin receptor mRNA in breast cancer tissue predicts poor prognosis for patients with high, but not low, serum leptin levels , 2006, International journal of cancer.
[44] I. Shih,et al. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. , 2004, The American journal of pathology.